[Form 3] DAXOR CORP Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

John Jefferies, Chief Medical Officer of DAXOR CORP (DXR), filed an Initial Statement of Beneficial Ownership reporting 15,272 shares of DAXOR common stock owned directly. The filing lists multiple stock options exercisable for a total of ≈18,181 underlying shares across various grant dates and strike prices, with several tranches vesting by 12/01/2025 and one option presently exercisable in full.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Jefferies John

(Last) (First) (Middle)

109 MECO LANE

(Street)

OAK RIDGE TN 37830

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
09/30/2025

3. Issuer Name and Ticker or Trading Symbol
DAXOR CORP [ DXR ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Daxor Common Stock	15,272	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	(1)	04/30/2028	Common Stock	885	$11.3	D
Stock Options (right to buy)	(2)	12/01/2027	Common Stock	14,660	$9.55	D
Stock Options (right to buy)	(1)	11/30/2027	Common Stock	539	$9.51	D
Stock Options (right to buy)	(1)	10/31/2027	Common Stock	283	$13.25	D
Stock Options (right to buy)	(1)	09/30/2027	Common Stock	236	$13.25	D
Stock Options (right to buy)	(1)	08/31/2027	Common Stock	309	$13.74	D
Stock Options (right to buy)	(1)	07/31/2027	Common Stock	448	$13.96	D
Stock Options (right to buy)	(1)	06/30/2027	Common Stock	284	$13.2	D
Stock Options (right to buy)	(1)	05/31/2027	Common Stock	406	$12.63	D
Stock Options (right to buy)	(1)	04/30/2027	Common Stock	327	$11.48	D
Stock Options (right to buy)	(1)	03/31/2027	Common Stock	364	$10.65	D
Stock Options (right to buy)	(1)	02/28/2027	Common Stock	469	$10.65	D
Stock Options (right to buy)	(1)	01/31/2027	Common Stock	380	$10.53	D
Stock Options (right to buy)	(1)	12/31/2026	Common Stock	199	$11.29	D
Stock Options (right to buy)	(1)	11/30/2026	Common Stock	216	$11	D
Stock Options (right to buy)	(1)	10/31/2026	Common Stock	116	$10.81	D
Stock Options (right to buy)	(1)	09/30/2026	Common Stock	353	$11.68	D
Stock Options (right to buy)	(1)	08/31/2026	Common Stock	221	$9.6	D
Stock Options (right to buy)	(1)	07/31/2026	Common Stock	275	$9.09	D
Stock Options (right to buy)	(1)	06/30/2026	Common Stock	224	$10.6	D
Stock Options (right to buy)	(1)	05/31/2026	Common Stock	147	$9.35	D
Stock Options (right to buy)	(1)	04/30/2026	Common Stock	129	$9.72	D
Stock Options (right to buy)	(1)	03/31/2026	Common Stock	145	$12.1	D

Explanation of Responses:

1. This option is presently exercisable in full.

2. The stock options will vest in three equal installments on December 1, 2023, December 1, 2024 and December 1, 2025.

	/s/ John Jefferies	09/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 3 for DAXOR CORP (DXR)?

John Jefferies, identified as Chief Medical Officer, filed the Form 3.

How many DAXOR common shares does John Jefferies report owning?

He reports owning 15,272 shares of DAXOR common stock directly.

What stock options are reported on the Form 3 for DXR?

The filing lists multiple stock options exercisable for common stock, including 885, 14,660, and several smaller tranches totaling about 18,181 underlying shares with strike prices from $9.09 to $13.96.

Are any options presently exercisable according to the filing?

Yes. The filing states that one option is presently exercisable in full.

When do the vesting tranches for the large option grant occur?

A large option grant vests in three equal installments on 12/01/2023, 12/01/2024, and 12/01/2025.